demonstrated that a glutamatergic receptor antagonist, widely used as medication for the treatment of AD, leads to reduced amyloid β-peptide production and plaque deposition by impairing the intracellular trafficking of the BACE substrate APP [66]. This evidence concerns the gene APP and Alzheimer disease.